OncoMatch/Clinical Trials/NCT05587543
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
Is NCT05587543 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including CAR and TCR for nasopharyngeal carcinoma.
Treatment: CAR · TCR — This study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.0 × 106 cells/kg, 1.5 × 107 cells/kg) of EBV CAR-T-cell therapy; The EBV TCR-T-cell group received three progressively increasing doses (5.0 × 106 cells/kg, 1.5 × 107 cells/kg, 3.0 × 107 cells/kg) of EBV TCR-T-cell therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV positive by in situ hybridization (Eber-FISH)
Ebv-positive nasopharyngeal carcinoma was diagnosed by in situ hybridization with Ebers (Eber-fish)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — recurrent/metastatic
Recurrent/metastatic nasopharyngeal carcinoma patients who had previously failed second-line or more systemic therapy
Cannot have received: Chimeric antigen receptor T-cell therapy
Treated with Chimeric antigen receptor t-cell therapy within six months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify